We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

PSMA PET Imaging Set to Become New Standard of Care for Detecting Prostate Cancer Metastases

By MedImaging International staff writers
Posted on 18 Feb 2022
Print article
Image: PSMA-Targeted Therapy in Prostate Cancer (Photo courtesy of Pexels)
Image: PSMA-Targeted Therapy in Prostate Cancer (Photo courtesy of Pexels)

PSMA PET imaging will soon become the new standard of care for detecting prostate cancer metastases, leading to improved care for these patients.

These are the latest findings of the Cleveland Clinic (Cleveland, OH, USA) which has ranked PSMA PET imaging at No. 2 on its list of the top 10 medical innovations to watch in 2022.

With a one in eight chance of diagnosis, prostate cancer is an ever-present worry for men. While many patients survive the disease, some develop metastatic cancer, which can lead to a poor outcome and possibly death. Early detection and imaging using CT and MRI scans are critical for staging and tumor location, but offer limited accuracy. Now, a promising new imaging technology has emerged, called prostate-specific membrane antigen positron emission tomography, or PSMA PET.

PSMA is an antigen found in high levels on the surface of prostate cancer cells and is a potential biomarker for disease. PSMA PET uses a radioactive tracer to locate and attach to PSMA proteins, which are then visible by PET. This targeted approach can be used in conjunction with CT or MRI scans to visualize where prostate cancer cells are residing. Results during phase three clinical trials showed substantially increased accuracy for detection of prostate metastasis compared to conventional imaging. FDA approved in 2021, experts say the PET tracer procedure will soon become the new standard of care for detecting prostate cancer metastasis, leading to improved care for these patients.

Related Links:
Cleveland Clinic 


Print article
CIRS -  MIRION
Sun Nuclear -    Mirion

Channels

Radiography

view channel
Image: The FDA has cleared the CSA system with Dynamic Digital Radiography (Photo courtesy of 20/20 Imaging)

Advanced Digital X-Ray System Allows Clinicians to Capture and Visualize Anatomy in Motion

Dynamic Digital Radiography (DDR) is a revolutionary X-ray technology that enables the visualization of anatomy in motion, so clinicians can interpret the dynamic interaction of anatomical structures,... Read more

Ultrasound

view channel
Image: EG-740UT ultrasound endoscope combined with ARIETTA 850 provides outstanding ultrasound image quality (Photo courtesy of FUJIFILM)

Next-Gen Ultrasound Endoscope Enables Complex Diagnostic and Therapeutic Procedures

Endoscopic ultrasound is a specialist procedure performed utilizing an endoscope equipped with an ultrasonic transducer which emits and receives ultrasonic waves within the gastrointestinal tract, such... Read more

Imaging IT

view channel
Illustration

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.